公开(公告)号：US08440168B2

公开(公告)日：2013-05-14

申请号：US12340338

申请日：2008-12-19

Applicant: David J. Yang ,  Chang-Sok Oh ,  Saady Kohanim ,  Dong-Fang Yu ,  Richard Mendez ,  E. Edmund Kim

Inventor： David J. Yang ,  Chang-Sok Oh ,  Saady Kohanim ,  Dong-Fang Yu ,  Richard Mendez ,  E. Edmund Kim

IPC: A61K51/04 ,  A61K49/00

CPC classification number: A61K51/0497 ,  A61K31/165 ,  C07C235/34 ,  C07F13/00 ,  C07F13/005

Abstract: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.

Abstract translation: 公开了用于成像和化疗和放射治疗的组合物和方法。 更具体地说，本发明涉及包含与乙二胺缀合或嵌入的β-肾上腺素能受体靶向化合物的靶向物质的试剂。 本发明还涉及这种用于心血管疾病成像和治疗的药剂的应用方法以及用于制备放射性标记的治疗剂或诊断剂的试剂盒。

公开(公告)号：US20090238756A1

公开(公告)日：2009-09-24

申请号：US12340338

申请日：2008-12-19

Applicant: David J. Yang ,  Chang-Sok Oh ,  Saady Kohanim ,  Dong-Fang Yu ,  Richard Mendez ,  E. Edmund Kim

Inventor： David J. Yang ,  Chang-Sok Oh ,  Saady Kohanim ,  Dong-Fang Yu ,  Richard Mendez ,  E. Edmund Kim

IPC: A61K51/04 ,  C07C233/40 ,  A61K49/00 ,  A61K49/22 ,  A61K31/165 ,  A61P9/00 ,  A61K49/04 ,  A61K49/10 ,  C07F13/00

CPC classification number: A61K51/0497 ,  A61K31/165 ,  C07C235/34 ,  C07F13/00 ,  C07F13/005

Abstract: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.

Abstract translation: 公开了用于成像和化疗和放射治疗的组合物和方法。 更具体地说，本发明涉及包含与乙二胺缀合或嵌入的β-肾上腺素能受体靶向化合物的靶向物质的试剂。 本发明还涉及这种用于心血管疾病成像和治疗的药剂的应用方法以及用于制备放射性标记的治疗剂或诊断剂的试剂盒。

公开(公告)号：US20080300389A1

公开(公告)日：2008-12-04

申请号：US12009421

申请日：2008-01-18

Applicant: David J. Yang ,  Dong-Fang Yu ,  I-Chien Wei

Inventor： David J. Yang ,  Dong-Fang Yu ,  I-Chien Wei

IPC: C07H15/00

CPC classification number: A61K33/24 ,  A61K31/282 ,  A61K47/61

Abstract: The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a monomeric amino acid having an O-group to a polysaccharide and by conjugating a metal to the O-group to form a polysaccharide conjugate. According to a third embodiment, the disclosure relates to a method of killing a cancer cell by administering to the cell an effective amount of a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid.

Abstract translation: 在一个实施方案中，本公开内容包括多糖缀合物。 该缀合物具有多糖和至少一个与多糖共价结合的具有O-基团的单体氨基酸。 缀合物还具有至少一种由氨基酸的O-基缀合的金属。 根据另一个实施方案，本公开提供了通过将具有O-基团的单体氨基酸与多糖共价键合并通过将金属与O基团缀合以形成多糖缀合物来合成多糖缀合物的方法。 根据第三实施方案，本公开涉及通过向细胞施用有效量的多糖缀合物来杀死癌细胞的方法。 该缀合物具有多糖和至少一个与多糖共价结合的具有O-基团的单体氨基酸。 缀合物还具有至少一种由氨基酸的O-基缀合的金属。

公开(公告)号：US20070297976A1

公开(公告)日：2007-12-27

申请号：US11760456

申请日：2007-06-08

Applicant: DAVID YANG ,  Chun Liu ,  Dong-Fang Yu ,  E. Kim

Inventor： DAVID YANG ,  Chun Liu ,  Dong-Fang Yu ,  E. Kim

IPC: A61B5/055 ,  A61K51/00 ,  A61P43/00

CPC classification number: A61K51/0497 ,  A61K51/0453 ,  A61K51/0459 ,  A61K51/0491 ,  A61K51/087 ,  A61K51/088

Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.

Abstract translation: 本发明在一般意义上提供了采用与乙二
氨酸（EC）螯合的99m Tc的新标记策略。 EC与各种配体缀合并螯合至99m Tc以用作组织特异性疾病的显像剂。 本发明的药物缀合物也可用作预后工具或用作将治疗剂递送至哺乳动物体内特定部位的工具。 还提供了用于组织特异性疾病成像的试剂盒。

公开(公告)号：US07229604B2

公开(公告)日：2007-06-12

申请号：US10672142

申请日：2003-09-26

Applicant: David J. Yang ,  Chun W. Liu ,  Dong-Fang Yu ,  E. Edmund Kim

Inventor： David J. Yang ,  Chun W. Liu ,  Dong-Fang Yu ,  E. Edmund Kim

IPC: A61K49/00

CPC classification number: A61K51/088 ,  A61K51/04 ,  A61K51/0478 ,  A61K51/0491 ,  A61K51/0497 ,  A61K51/087

Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.

Abstract translation: 本发明在一般意义上提供了采用与乙二
氨酸（EC）螯合的99m Tc的新标记策略。 EC与各种配体缀合并螯合至99m Tc以用作组织特异性疾病的显像剂。 本发明的药物缀合物也可用作预后工具或用作将治疗剂递送至哺乳动物体内特定部位的工具。 还提供了用于组织特异性疾病成像的试剂盒。

公开(公告)号：US20060188438A1

公开(公告)日：2006-08-24

申请号：US11405334

申请日：2006-04-17

Applicant: David Yang ,  Chun Liu ,  Dong-Fang Yu ,  E. Kim

Inventor： David Yang ,  Chun Liu ,  Dong-Fang Yu ,  E. Kim

IPC: A61K51/00 ,  C07F13/00

CPC classification number: A61K51/088 ,  A61K51/04 ,  A61K51/0478 ,  A61K51/0491 ,  A61K51/0497 ,  A61K51/087

Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.

公开(公告)号：US20060135404A1

公开(公告)日：2006-06-22

申请号：US11285392

申请日：2005-11-23

Applicant: Chun Li ,  Sidney Wallace ,  Dong-Fang Yu ,  David Yang

Inventor： Chun Li ,  Sidney Wallace ,  Dong-Fang Yu ,  David Yang

IPC: A61K38/16

CPC classification number: A61K41/0038 ,  A61K31/337 ,  A61K31/4375 ,  A61K38/13 ,  A61K47/547 ,  A61K47/59 ,  A61K47/60 ,  A61K47/645 ,  A61K51/0497 ,  A61K51/065 ,  A61K2121/00 ,  A61K2123/00 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/606 ,  C08G73/1092

Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

公开(公告)号：US07060724B2

公开(公告)日：2006-06-13

申请号：US10354431

申请日：2003-01-30

Applicant: Chun Li ,  Sidney Wallace ,  Dong-Fang Yu ,  David J. Yang

Inventor： Chun Li ,  Sidney Wallace ,  Dong-Fang Yu ,  David J. Yang

IPC: A01N43/02 ,  C07D305/00

CPC classification number: A61K41/0038 ,  A61K31/337 ,  A61K31/4375 ,  A61K38/13 ,  A61K47/547 ,  A61K47/59 ,  A61K47/60 ,  A61K47/645 ,  A61K51/0497 ,  A61K51/065 ,  A61K2121/00 ,  A61K2123/00 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/606 ,  C08G73/1092

Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

公开(公告)号：US07008633B2

公开(公告)日：2006-03-07

申请号：US10024678

申请日：2001-12-18

Applicant: David J. Yang ,  Dong-Fang Yu ,  Ali Azhdarinia ,  Tommy L. Lee ,  E. Edmund Kim

Inventor： David J. Yang ,  Dong-Fang Yu ,  Ali Azhdarinia ,  Tommy L. Lee ,  E. Edmund Kim

IPC: A61F13/00 ,  A61K9/14 ,  A61K48/00

CPC classification number: A61K51/1255 ,  A61K9/0024 ,  A61K9/1652 ,  A61K31/717 ,  A61K31/718 ,  A61K31/721 ,  A61K31/722 ,  A61K31/728 ,  A61K31/729 ,  A61K47/183 ,  A61K47/36 ,  A61K47/38 ,  A61K47/6903 ,  A61K51/06 ,  A61K51/1213

Abstract: Methods regarding local regional treatment in situ for an individual, such as of a tumor, are provided herein. A hydrogel composition is generated in situ in the tumor by administering a polymer, such as a polysaccharide or a polyamino acid, with a therapeutic agent, such as a radionuclide or a drug, and administering a cross-linking agent. The hydrogel/therapeutic agent composition is retained in the tumor for safe and efficient tumor therapy. Alternatively, a hydrogel composition is generated in situ in an artery which nourishes a tumor to occlude the artery.

Abstract translation: 本文提供了关于个体如肿瘤的原位局部局部治疗的方法。 通过使用诸如多糖或多氨基酸的聚合物与治疗剂如放射性核素或药物一起在肿瘤中原位产生水凝胶组合物，并施用交联剂。 水凝胶/治疗剂组合物保留在肿瘤中用于安全和有效的肿瘤治疗。 或者，在动脉中产生水凝胶组合物，该动脉会滋养肿瘤以闭塞动脉。

公开(公告)号：US06730699B2

公开(公告)日：2004-05-04

申请号：US10300031

申请日：2002-11-20

Applicant: Chun Li ,  Sidney Wallace ,  Dong-Fang Yu ,  David Yang

Inventor： Chun Li ,  Sidney Wallace ,  Dong-Fang Yu ,  David Yang

IPC: A61K31335

CPC classification number: A61K41/0038 ,  A61K31/337 ,  A61K31/4375 ,  A61K38/13 ,  A61K47/547 ,  A61K47/59 ,  A61K47/60 ,  A61K47/645 ,  A61K51/0497 ,  A61K51/065 ,  A61K2121/00 ,  A61K2123/00 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/606 ,  C08G73/1092

Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.